Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda

AIDS Research and Human Retroviruses

Volumn 22, Issue 10, 2006, Pages 985-992

  Gale, Catherine V ^a   Yirrell, David L ^b,c,d   Campbell, Eileen ^c   Van Der Paal, Lieve ^d   Grosskurth, Heiner ^d   Kaleebu, Pontiano ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN;

ARTICLE; CODON; COHORT ANALYSIS; DNA POLYMORPHISM; FEMALE; GENETIC RECOMBINATION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RURAL AREA; STRUCTURAL GENE; UGANDA; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CODON; COHORT STUDIES; GENES, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PHYLOGENY; UGANDA; VARIATION (GENETICS);

EID: 33846217459     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.985     Document Type: Article

References (41)

1. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, and Korber B: HIV-1 nomenclature proposal. Science 2000;288(5463):55-56.
2. Gomez-Carrillo M, Quarleri JF, Rubio AE, Carobene MG, Dilernia D, Carr JK, and Salomon H: Drug resistance testing provides evidence of the globalization of HIV type 1: A new circulating recombinant form. AIDS Res Hum Retroviruses 2004;20(8):885-888.
3. Kijak GH and McCutchan FE: HIV diversity, molecular epidemiology, and the role of recombination. Curr Infect Dis Rep 2005;7(6):480-488.
4. Kantor R and Katzenstein D: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5(1):25-35.
5. Yirrell DL, Shaw L, Burns SM, Cameron SO, Quigg M, Campbell E, and Goldberg D: HIV-1 subtype in Scotland: The establishment of a national surveillance system. Epidemiol Infect 2004;132(4):693-698.
6. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, and Eshleman SH: Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000;16(8):807-813.
7. Weidle PJ, Kityo CM, Mugyenyi P, Downing R, Kebba A, Pieniazek D, Respess R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, and Lackritz E: Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr 2001;26(5):495-500.
8. Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C, Mugyenyi P, Petropoulos C, and Arts EJ: Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. J Virol 2004;78(10):5390-5401.
9. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, and Eshleman SH: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14(11):F111-115.
10. Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, and Jackson JB: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005;40(1):24-29.
11. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, and Arts EJ: High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004;20(4):355-364.
12. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, and Tong CY: K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005;19(16):1916-1919.
13. Eshleman SH, Gonzales MJ, Becker-Pergola G, Cunningham SC, Guay LA, Jackson JB, and Shafer RW: Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D. AIDS Res Hum Retroviruses 2002;18(7):507-511.
14. Morgan D, Malamba SS, Maude GH, Okongo MJ, Wagner HU, Mulder DW, and Whitworth JA: An HIV-1 natural history cohort and survival times in rural Uganda. AIDS 1997;11(5):633-640.
15. Morgan D, Rutebemberwa A, Malamba S, Ross A, Whitworth J, Kaleebu P, and Gotch F: HIV-1 RNA levels in an African population-based cohort and their relation to CD4 lymphocyte counts and World Health Organization clinical staging. J Acquir Immune Defic Syndr 1999;22(2):167-173.
16. Kaleebu P, Whitworth J, Hamilton L, Rutebemberwa A, Lyagoba F, Morgan D, Duffield M, Biryahwaho B, Magambo B, and Oram J: Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. AIDS Res Hum Retroviruses 2000;16(5):1393-401.
17. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, Lyagoba F, Hamilton L, Biryahwaho B, and Whitworth J: Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001;15(3):293-299.
18. Yirrell DL, Kaleebu P, Morgan D, Watera C, Magambo B, Lyagoba F, and Whitworth J: Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS 2002;16(2):279-286.
19. Senkaali D, Muwonge R, Morgan D, Yirrell D, Whitworth J, and Kaleebu P: The relationship between HFV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res Hum Retroviruses 2004;20(9):932-937.
20. Yirrell DL, Kaleebu P, Morgan D, Hutchinson S, and Whitworth JA: HIV-1 subtype dynamics over 10 years in a rural Ugandan cohort. Int J STD AIDS 2004;15(2):103-106.
21. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, and Markowitz M: HIV-1 drug resistance in newly infected individuals. JAMA 1999;282(12):1135-1141.
22. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, and Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-394.
23. Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, and Lackritz E: Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda. AIDS 2003;17(Suppl 3):S39-48.
24. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D, and Katzenstein DA: HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18(18):1407-1413.
25. Mulder DW, Nunn AJ, Kamali A, Nakiyingi J, Wagner HU, and Kengeya-Kayondo JF: Two-year HIV-1-associated mortality in a Ugandan rural population. Lancet 1994;343(8904):1021-1023.
26. Higgins DG: CLUSTAL V: Multiple alignment of DNA and protein sequences. Methods Mol Biol 1994;25:307-318.
27. Kumar S, Tamura K, Jakobsen IB, and Nei M: MEGA2: Molecular evolutionary genetics analysis software. Bioinformatics 2001;17(12):1244-1245.
28. Gale CV, Myers R, Tedder RS, Williams IG, and Kellam P: Development of a novel human immunodeficiency virus type 1 subtyping tool, Subtype Analyzer (STAR): Analysis of subtype distribution in London. AIDS Res Hum Retroviruses 2004;20(5);457-464.
29. Myers RE, Gale CV, Harrison A, Takeuchi Y, and Kellam P: A statistical model for HIV-1 sequence classification using the sub-type analyser (STAR). Bioinformatics 2005;21(17):3535-3540.
30. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, and Ray SC: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73(1):152-160.
31. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, and Richman D: Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med 2005;13(1):51-57.
32. Spira S, Wainberg MA, Loemba H, Turner D, and Brenner BG: Impact of clade diversity on HTV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003;51(2):229-240.
33. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Scares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, and Shafer RW: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):e112.
34. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, and Delaporte E: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38(11):3919-3925.
35. Gonzales MJ, Machekano RN, and Shafer RW: Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001;184(8):998-1006.
36. Harris ME, Serwadda D, Sewankambo N, Kim B, Kigozi G, Kiwanuka N, Phillips JB, Wabwire F, Meehen M, Lutalo T, Lane JR, Merling R, Gray R, Wawer M, Birx DL, Robb ML, and McCutchan FE: Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 2002;18(17):1281-1290.
37. Renjifo B, Gilbert P, Chaplin B, Vannberg F, Mwakagile D, Msamanga G, Hunter D, Fawzi W, and Essex M: Emerging recombinant human immunodeficiency viruses: Uneven representation of the envelope V3 region. AIDS 1999;13(13):1613-1621.
38. Erickson JW, Gulnik SV, and Markowitz M: Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999;13(Suppl A):S189-204.
39. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R, et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92(6):2398-2402.
40. Kijak GH, Currier JR, Tovanabutra S, Cox JH, Michael NL, Wegner SA, Birx DL, and McCutchan FE: Lost in translation: Implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev 2004;6(1):54-60.
41. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31(1):298-303.